X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.globenewswire.com//news-release/2023/09/05/2737266/0/en/Cingulate-Announces-Presentation-of-Full-Trial-Results-from-Phase-3-Adult-Efficacy-and-Safety-Trial-of-CTx-1301-dexmethylphenidate-for-ADHD-at-Psych-Congress-2023.html
https://www.prnewswire.com/news-releases/journal-frontiers-in-psychiatry-publishes-analysis-of-open-label-safety-study-showing-improvements-in-sleep-habits-for-children-with-adhd-after-treatment-with-azstarys-serdexmethylphenidate-and-dexmethylphenidate-301862645.html
https://www.globenewswire.com/news-release/2023/06/08/2684589/0/en/Cingulate-Completes-Phase-3-Adult-Trial-of-CTx-1301-dexmethylphenidate-for-ADHD.html
https://www.prnewswire.com/news-releases/coriums-novel-adhd-medication-azstarys-serdexmethylphenidate-and-dexmethylphenidate-had-no-clinically-significant-impact-on-childrens-weight-and-height-growth-rate-301830739.html
https://www.globenewswire.com/news-release/2023/05/03/2660133/0/en/Cingulate-Announces-Successful-Transfer-of-CTx-1301-dexmethylphenidate-Proprietary-PTR-Manufacturing-Processes-to-Societal-CDMO.html
https://www.prnewswire.com/news-releases/coriums-novel-adhd-medication-azstarys-serdexmethylphenidate-and-dexmethylphenidate-shown-safe-and-effective-in-long-term-study-301752562.html
https://www.prnewswire.com/news-releases/corium-to-present-positive-data-on-adhd-medication-azstarys-serdexmethylphenidate-and-dexmethylphenidate-and-alzheimers-disease-medication-adlarity-donepezil-transdermal-system-at-psych-congress-2022-301622663.html
https://www.biospace.com/article/releases/serdexmethylphenidate-a-prodrug-of-dexmethylphenidate-and-contained-in-corium-s-adhd-medication-azstarys-serdexmethylphenidate-and-dexmethylphenidate-has-low-relative-potential-for-abuse/
https://www.prnewswire.com/news-releases/corium-to-present-at-academy-of-managed-care-pharmacy-fast-acting-azstarys-serdexmethylphenidate-and-dexmethylphenidate-significantly-improves-attention-and-behavior-in-children-aged-6-to-12-years-with-adhd-301511349.html
https://www.asiaone.com/business/ark-biopharmaceutical-enters-exclusive-license-agreement-novel-adhd-treatment-azstarys
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215523
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206734
https://www.prnewswire.com/news-releases/once-daily-azstarys-serdexmethylphenidate-and-dexmethylphenidate-first-and-only-product-containing-dexmethylphenidate-prodrug-for-adhd-in-patients-aged-6-years-and-older-significantly-reduces-adhd-symptoms-301399896.html
https://www.renaissancecapital.com/IPO-Center/News/86502/ADHD-drug-developer-Cingulate-sets-terms-for-$50-million-IPO#:~:text=Cingulate%2C%20a%20Phase%203%2Dready,range%20of%20%2410%20to%20%2412.
https://www.prnewswire.com/news-releases/corium-secures-235-million-in-debt-financing-301384817.html
https://www.globenewswire.com/news-release/2021/03/03/2185820/0/en/KemPharm-Announces-FDA-Approval-of-AZSTARYS-serdexmethylphenidate-and-dexmethylphenidate-capsules-for-oral-use-CII-A-New-Once-Daily-Treatment-for-ADHD.html
https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-novel-once-daily-capsule-azstarys-serdexmethylphenidate-and-dexmethylphenidate-first-and-only-product-containing-dexmethylphenidate-prodrug-for-adhd-in-patients-age-6-years-and-older-301240023.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213813
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209754
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209754
https://www.raps.org/news-and-articles/news-articles/2019/9/fda-consults-on-abuse-deterrent-cns-stimulants
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212631
https://www.adarepharma.com/press-release/dexmethylphenidate-hydrochloride/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210279
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209211
https://www.prnewswire.com/news-releases/bdd-pharma-and-cingulate-therapeutics-announce-license-agreement-with-oralogik-enabled-triple-pulse-products-852204650.html
https://www.drugdeliverybusiness.com/cingulate-raises-7-5m-for-controlled-release-adhd-therapy/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208756
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209468
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202731
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203614
http://www.prnewswire.com/news-releases/impax-announces-fda-approval-and-launch-of-additional-strengths-of-generic-focalin-xr-dexmethylphenidate-hydrochloride-extended-release-capsules-cii-300483625.html
http://www.prnewswire.com/news-releases/shangpharma-innovation-appoints-mohamad-moghadam-tabrizi-as-senior-vice-president-of-business-development-300462926.html
https://globenewswire.com/news-release/2017/01/06/904004/0/en/Intellipharmaceutics-Reports-on-Launch-of-Additional-Strengths-of-Generic-Focalin-XR-by-Par-Pharmaceutical.html
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202842
https://www.pharmacompass.com/pdf/news/pfizers-quillichew-er-approved-in-us-for-attention-deficit-hyperactivity-1449575699.pdf
http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-corporateNewsArticle&ID=2023664
Market Place
Share 
